Stocktoria
TherapeuticsMD, Inc. TXMD
TherapeuticsMD, Inc. (TXMD) earns a Piotroski F-score of 5/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $3.0M at a -18.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
| UPB | Upstream Bio, Inc. | 2/9 | — | — | — |
| RNAC | Cartesian Therapeutics, Inc. | 1/9 | -10.08 | — | -92.8% |
| ONTX | Traws Pharma, Inc. | 3/9 | — | 1.4 | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
| MRKR | Marker Therapeutics, Inc. | 2/9 | — | — | — |
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
FAQ
Is TXMD financially healthy?
TherapeuticsMD, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak).
Does TXMD pay a dividend?
No, TherapeuticsMD, Inc. does not currently pay a dividend.
How profitable is TXMD?
In FY2025, TherapeuticsMD, Inc. had a net margin of -18.8% and a return on equity of -2.1%.
Is TXMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TherapeuticsMD, Inc.: a Piotroski F-score of 5/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.